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ABSTRACT Recognition modes of individual T cell receptors (TCRs) are well studied,
but factors driving the selection of TCR repertoires from primary through persistent
human virus infections are less well understood. Using deep sequencing, we
demonstrate a high degree of diversity of Epstein-Barr virus (EBV)-specific clono-
types in acute infectious mononucleosis (AIM). Only 9% of unique clonotypes de-
tected in AIM persisted into convalescence; the majority (91%) of unique clono-
types detected in AIM were not detected in convalescence and were seeming
replaced by equally diverse “de novo” clonotypes. The persistent clonotypes had a
greater probability of being generated than nonpersistent clonotypes due to conver-
gence recombination of multiple nucleotide sequences to encode the same amino
acid sequence, as well as the use of shorter complementarity-determining regions 3
(CDR3s) with fewer nucleotide additions (i.e., sequences closer to germ line). More-
over, the two most immunodominant HLA-A2-restricted EBV epitopes, BRLF1109 and
BMLF1280, show highly distinct antigen-specific public (i.e., shared between indi-
viduals) features. In fact, TCR CDR3 motifs played a dominant role, while TCR
played a minimal role, in the selection of TCR repertoire to an immunodominant
EBV epitope, BRLF1. This contrasts with the majority of previously reported rep-
ertoires, which appear to be selected either on TCR CDR3 interactions with
peptide/major histocompatibility complex (MHC) or in combination with TCR
CDR3. Understanding of how TCR-peptide-MHC complex interactions drive reper-
toire selection can be used to develop optimal strategies for vaccine design or
generation of appropriate adoptive immunotherapies for viral infections in trans-
plant settings or for cancer.
IMPORTANCE Several lines of evidence suggest that TCR and TCR repertoires
play a role in disease outcomes and treatment strategies during viral infections in
transplant patients and in cancer and autoimmune disease therapy. Our data sug-
gest that it is essential that we understand the basic principles of how to drive opti-
mum repertoires for both TCR chains,  and . We address this important issue by
characterizing the CD8 TCR repertoire to a common persistent human viral infection
(EBV), which is controlled by appropriate CD8 T cell responses. The ultimate goal
would be to determine if the individuals who are infected asymptomatically develop
a different TCR repertoire than those that develop the immunopathology of AIM.
Here, we begin by doing an in-depth characterization of both CD8 T cell TCR and
TCR repertoires to two immunodominant EBV epitopes over the course of AIM,
identifying potential factors that may be driving their selection.
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Over 95% of the world’s population is persistently infected with Epstein-Barr virus(EBV) by the fourth decade of life. In the 30% of individuals who are EBV
serologically negative upon entering college, primary infection can result in the syn-
drome acute infectious mononucleosis (AIM); the frequency of reported symptomatic
disease has varied from 25 to 77% of these young adults (1, 2). AIM symptoms can vary
greatly in severity from a mild short flu-like illness to a more severe syndrome with sore
throat, lymphadenopathy, splenomegaly, hepatomegaly, and debilitating fatigue,
which may last for months (1, 2). However, primary infection in the majority of
individuals occurs in young childhood and is essentially asymptomatic, rarely develop-
ing into AIM. A rare 5% of the population appear to never acquire infection and remain
EBV serologically negative; severe illness requiring hospitalization has been reported in
individuals who acquire primary EBV infection late in life (3). A history of AIM has been
associated with an increased risk of subsequent multiple sclerosis (MS) (4) or Hodgkin’s
lymphoma (5). EBV infection is also associated with Burkitt lymphoma, nasopharyngeal
cancer, hairy leukoplakia in individuals with AIDS, and lymphoproliferative malignan-
cies in transplant patients (5, 6). EBV-associated posttransplant lymphoproliferative
disorders can be prevented or treated by adoptive transfer of EBV-specific CD8 T cells
(6–8). Defective CD8 T cell control of EBV reactivation may also result in the expansion
of EBV-infected, autoreactive B cells in MS (9). Improvement of MS has followed infusion
of autologous EBV-specific CD8 T cells in some patients but not others, suggesting that
there may be qualitative differences in EBV-specific CD8 T cell responses that need to
be better understood (4).
Altogether, these data indicate that EBV-specific CD8 T cells are important for viral
control (10). The integration of computational biology and structural modeling ap-
proaches to identify T cell receptor (TCR) antigen specificity groups and TCR features
associated with virologic control (11–16) would facilitate our understanding of how
EBV-specific CD8 T cells control EBV replication and contribute to the development of
a vaccine to prevent or immunotherapies to modify EBV infection (7, 8, 17).
One of the hallmarks of CD8 T cells is epitope specificity, conferred by the interac-
tion of the T cell receptor (TCR) with virus-derived peptides bound to host major
histocompatibility complex (pMHC) (18–21). The TCR is a membrane-bound, heterodi-
meric protein composed of  and  chains. Each chain arises from rearrangement of
variable (V), diversity (D), joining (J), and constant (C) gene segments (22), resulting in
a diverse pool of unique TCR and TCR clonotypes. Additions or deletions of N
nucleotides at the V(D)J junctions, specifically at the complementarity-determining
region 3 (CDR3) and pairing of different TCR and TCR segments further enhance the
diversity of the TCR repertoire, estimated to range from 1015 to 1020 unique potential
TCR clonotypes (23, 24). This diversity allows CD8 T cell responses to a myriad of
pathogens.
The CD8 TCR repertoire is an important determinant of CD8 T cell-mediated antiviral
efficacy or immune-mediated pathology (16, 23, 25–28). Defining the relationships
between early and memory CD8 TCR repertoires is important to understanding struc-
tural features of the TCR repertoire that govern the selection and persistence of CD8 T
cells in memory. Deep-sequencing techniques, combined with structural analyses,
provide a high-throughput and unbiased approach to understanding antigen-specific
TCR repertoires. We (29) and others (30–33) have recently reported that TCR
repertoires of CD8 T cell responses to common viruses (influenza virus, cytomegalovirus
[CMV], and hepatitis C virus) are highly diverse and individualized (i.e., “private”) but
that “public” clonotypes (defined as the same V, J, or CDR3 amino acid sequences in
many individuals) are favored for expansion, likely due to selection for optimal struc-
tural interactions (34).
Studies of influenza A virus (IAV) in mice (35) and simian immunodeficiency virus
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(SIV) in rhesus macaques (36) have shown that the efficiency with which TCR se-
quences are produced via V(D)J recombination is an important determinant of the
extent of TCR sharing between individuals (35, 37). Shared TCR amino acid se-
quences required fewer nucleotide additions and were encoded by a greater variety of
nucleotide sequences (i.e., convergent recombination). Both of these features are
characteristics of TCR sequences that have the potential to be produced frequently
(35–39) and are also observed in many public TCRs (29, 30, 38–41).
To thoroughly evaluate molecular features of TCR that are important for driving
repertoire selection over time following EBV infection, we used direct ex vivo deep
sequencing of both TCR V and V regions of CD8 T cells specific to two immuno-
dominant epitopes, BRLF-1109 (YVL-BR) and BMLF-1280 (GLC-BM), isolated from periph-
eral blood during primary EBV infection (AIM) and 6 months later in convalescence
(CONV). Each TCR repertoire had a high degree of diversity. However, we noted that
persistent clonotypes accounted for only 9% of the unique clonotypes and yet they
predominated in both the acute and convalescent phases of infection. An interesting
corollary of this finding was that 91% of the unique clonotypes expanded in acute
infection were not expanded in convalescence, appearing to be replaced in 6 months
by an equally diverse set of de novo clonotypes. Expanded clonotypes detected in AIM
and CONV were more likely to be generated in part as a result of convergent recom-
bination than nonpersistent or de novo clonotypes and had distinct public features
(meaning they are shared between donors), which varied by the specific epitope.
RESULTS
Patient characteristics. Three HLA-A*02:01 individuals presenting with symptoms
of AIM and laboratory studies consistent with primary infection were studied (see
Table S1 in the supplemental material) at initial clinical presentation (AIM) and
6 months later (CONV). Direct tetramer staining of peripheral blood revealed that
2.1%  0.5% (mean  standard error of the mean [SEM]) and 1.1%  0.3% of CD8 T
cells were YVL-BR and GLC-BM specific, respectively, in AIM and declined to 0.3% 
0.2% and 0.3% 0.1%, respectively, in CONV. Mean blood EBV load was 3.8 0.9 log10
genome copies/106 B cells in AIM and 2.6 0.7 log10 genome copies/106 B cells in
CONV.
Persistent dominant clonotypes represent a small fraction of unique clono-
types, with TCR and TCR repertoire diversity maintained by the development
of de novo clonotypes. To examine features that drive selection of YVL-BR- and
GLC-BM-specific TCRs in AIM and CONV, deep sequencing of TCR and TCR reper-
toires was conducted directly ex vivo on tetramer-sorted CD8 T cells at both time points
(Fig. 1, Fig. S1 and S2, and Table S2). YVL-BR- and GLC-BM-specific CD8 TCR repertoires
in AIM demonstrated interindividual differences and were highly diverse; the mean
(SEM) number of unique clonotypes (defined as a unique DNA rearrangement) was
not significantly different in CONV (Fig. 1). Each unique TCR or TCR clonotype
detected in AIM that was also detected in CONV was defined as a “persistent” clono-
type. Clonotypes were regarded as “nonpersistent” or “de novo” if they were detected
only during AIM or CONV, respectively. A high level of TCR diversity was maintained
from AIM to CONV; however, the number of overlapping unique clonotypes detected
in both AIM and CONV was small (Fig. 1, panels i). Only a small fraction of TCR or TCR
unique clonotypes specific to YVL-BR (6.6% 2.2%) and GLC-BM (9.1% 4.2%) that
were present in AIM were maintained in CONV (YVL-BR, 8.7% 4.9%; GLC-BM,
18.5% 5.6%). However, they comprised 57.5% 26.2% (YVL-BR) or 75.5% 12%
(GLC-BM) of the total CD8 T cell response when including their frequency (sequence
reads) in AIM and 35.8% 10.2% (YVL-BR) or 55.8% 13.4% (GLC-BM) in CONV (Fig. 1,
panels ii). While the clonotypic composition of YVL-BR- and GLC-BM-specific CD8 T cells
changed over the course of primary infection, dominant TCR clonotypes detected
during AIM tended to persist and dominate in CONV. Altogether, these data indicate
that persistent clonotypes made up only a small percentage of unique clonotypes but
were highly expanded in AIM and CONV. Surprisingly, the vast majority (91%) of unique
Selection of EBV-Specific CD8 TCR Repertoire in AIM ®
March/April 2020 Volume 11 Issue 2 e00250-20 mbio.asm.org 3
 o
n
 April 15, 2020 at UNIV O
F M
ASS M
ED SCH
http://m
bio.asm
.org/
D
ow
nloaded from
 
clonotypes were not detected following AIM and were seemingly replaced with de novo
clonotypes in CONV.
Persistent public clonotypes have an increased probability of generation;
convergent recombination contributes to the selection of the persistent TCR and
TCR repertoire. In both the YVL-BR and GLC-BM TCR repertoires, the percentage of
public clonotypes significantly increased (chi-square test: P 0.0001) in the persistent
(for YVL-BR, TCRAV, 34%, and TCRBV, 17%; for GLC-BM, TCRAV, 27%, and TCRBV, 22%)
compared to the nonpersistent (for YVL-BR, TCRAV, 5%, and TCRBV, 2%; for GLC-BM,
TCRAV, 4%, and TCRBV, 4%) or de novo (for YVL-BR, TCRAV, 5%, and TCRBV, 1%; for
GLC-BM, TCRAV, 6%, and TCRBV, 7%) repertoire. This suggests that the persistent
clonotypes may have TCR features that led to greater probability of generation. We
tested this by directly calculating the generation probability of amino acid sequences
in the CDR3 to determine if the public clonotypes are easier to generate than the
private at both time points, acute and convalescent. This allowed a direct and rigor-
ously quantitative test of whether the expanded persistent public clonotypes were of
higher generation probability (39, 42). The TCR sequences used by dominant public
TCRAV of either GLC-BM- or YVL-BR-specific responses have a significantly greater
probability of generation while only the GLC-BM TCRBV public but not the YVL-BR
public repertoire has a greater probability of being generated (Fig. 2). This might
suggest that TCRAV is dominant and important in the selection of YVL-BR TCR reper-
toire, while both TCRAV and TCRBV contribute to the GLC-BM TCR repertoire.
To further study this issue, we examined whether convergent recombination played
a role in the generation of these public persistent TCRs (39). Examination of memory
antiviral TCR repertoires in humans, mice, and macaques suggests that convergent
recombination plays an important role in the selection of public antigen-specific TCRs
(i.e., those shared between individuals of the same haplotype) (35–37). Consistent with
previous reports for epitope-specific CD8 TCR (37, 43, 44), our group found that
convergent recombination plays an important role in EBV-specific TCR repertoire
selection. We also demonstrated that convergent recombination plays a role in selec-
tion of persistent TCR clonotypes specific for the two immunodominant EBV epitopes,
YVL-BR and GLC-BM, during the course of a human viral infection. There was an
increased usage of amino acids derived by multiple different nucleotide sequences in
the CDR3 and CDR regions of persistent clonotypes compared to nonpersistent and
YVL-BR GLC-BM
AIM CONV AIM CONV AIM CONV AIM CONV
Unique clonotypes % of total CD8 T-cell
response
TCRA
TCRB
Unique clonotypes % of total CD8 T-cell
response
5548
(±3668)
2981
(±1629)
13,494,884
(±6,992,998)
13,694,140
(±6,583,419)
9035
(±5557)
3899
(±1085)
15,149,456
(±5,419,538)
15,433,080
(±4,716,498)
4202
(±3087)
3982
(±1468)
16,455,477
(±6,930,810)
20,245,543
(±3,186,229)
4540
(±1781)
4964
(±1973)
19,760,962
(±7,488,339)
17,416,329
(±3,127,535)
(A) (B)
(i) (i)
PersistentNon-persistent De Novo
6.6%
 2.2%
11.7%
 2.9%
57.5%
 26.2%
51.3%
 11.1%
9%
 4.2%
18.5%
 5.6%
72.8%
 23.1%
55.8%
 13.4%
9%
 1.7%
9.1%
 5%
61.4%
 8.5%
35.8%
 10.2%
9.1%
 4.2%
8.7%
 4.9%
75.5%
 12%
48.9%
 21%
(ii) (ii)
FIG 1 Persistent dominant clonotypes represent a small fraction of unique clonotypes, with TCR and TCR repertoire
diversity maintained by the development of de novo clonotypes. (i) Clonotypes that persist from the acute phase into
memory represent only 6 to 18% of the unique clonotypes but contribute to 35 to 75% of the total CD8 T cell response.
The highly diverse nonpersistent clonotypes are replaced by new (de novo) highly diverse clonotypes, which were not
present in the acute response. The average frequency of unique clonotypes that persist into the memory phase (TRAV and
TRBV) in total HLA-A2/YVL-BR-specific (A) and GLC-BM-specific (B) TCR repertoire is shown (i). The average numbers (SEM)
of unique clonotypes from the 3 donors are shown below the pie charts. Also shown in the pie charts is the percentage
that these clonotypes contribute to the total CD8 T cell response in the HLA-A2/YVL-BR-specific (A) and GLC-BM-specific
(B) TCR repertoire (ii). The average numbers (SEM) of sequence reads are shown below the pie charts.
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de novo clonotypes (Fig. 3A and C). In fact, we show here that the public TCR had
significantly greater usage of these types of amino acids in the CDR3, as well as the
CDR3 (Fig. 3B and D), compared to the private clonotypes.
Another TCR feature that leads to increased probability of generation is the use of
decreased numbers of nucleotide additions in the CDR3, consistent with encoding of
A. 
B. 
FIG 2 Increased probability of generation of dominant public persistent clonotypes. The algorithm OLGA was used to calculate the generation probability of
TCR sequences (42). The public TCRAV sequences (A) of either the GLC-BM (BM)- or YVL-BR-(BR)-specific repertoire had a significantly greater probability of
generation than private sequences. Only the public TCRBV (B) sequences of the GLC-BM but not YVL-BR repertoire had a greater probability of being generated
than the private sequences. This is highly consistent with our observation that TCRAV plays a much greater role in the peripheral selection of the YVL-BR TCR
repertoire than does TCRBV. The differences between public and private in each pair are all significant (Wilcoxon test, P 0.0001) except for TCRBV BR V1 (acute
visit 1) and V7 (CONV visit 7).
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the TCR by predominantly germ line gene segments (39). This was indeed the case for
YVL-BR- and GLC-BM-specific clonotypes (Fig. 4); the CDR3 of persistent YVL-BR- and
GLC-BM-specific clonotypes had fewer nucleotide additions than nonpersistent clono-
types and an increased number of nucleotide additions in de novo clonotypes of
EBV-BR. However, the CDR3 of persistent YVL-BR- and GLC-BM-specific clonotypes did
not have fewer nucleotide additions than nonpersistent clonotypes (Fig. 4A and D).
Public clonotypes of each epitope-specific response also had fewer nucleotide addi-
tions than private clonotypes, except interestingly for YVL-BR CDR3, where the private
clonotypes had fewer (Fig. 4B and E). Interestingly, there was an increased usage of
glycines in the longer CDR3 of the de novo TCR repertoire (Fig. 4C and F), which has
been reported to be a feature associated with greater TCR promiscuity (45, 46). Overall,
these results suggest the use of shorter CDR3s with fewer nucleotide additions in the
persistent TCRAV but not in the TCRBV clonotypes. Curiously, consistent with proba-
bility generation data (Fig. 2), the public TCRBV of EBV-BR were actually significantly
longer with increased nucleotide additions.
CDR3 lengths are a major factor in the selection of the YVL-BR- and GLC-BM-
specific TCR and TCR repertoires. Differences in dominant YVL-BR- and GLC-BM-
specific CDR3 and CDR lengths were also observed between the epitopes and from
AIM to CONV and between persistent and nonpersistent or de novo clonotypes (Fig. 5).
There were differences in preferential use of CDR3 lengths between YVL-BR and
GLC-BM. For instance, the AIM YVL-BR-specific repertoire used more of the shorter
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FIG 3 Convergent recombination drives selection of persistent but not nonpersistent TCR repertoire:
increased usage in CDR3 of amino acids derived by multiple different nucleotide sequences. Shown is the
number of nucleotides encoding amino acid sequence in CDR3 of YVL-BR-specific (A and B) and
GLC-BM-specific (C and D) TCR and TCR of persistent, nonpersistent, and de novo repertoires (A and
C) and private versus public clonotypes (B and D). (A public TCR is defined as more than one donor using
that clonotype based on amino acid sequence.) Data were analyzed by multivariant two-way ANOVA
with correction for multiple comparisons. *, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001. Error
bars are SEM.
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10-mer CDR3 than GLC-BM in both AIM and CONV (Fig. 5A, panel ii). Within the YVL-BR
response, use of the shorter 9-mer CDR3 decreased from AIM to CONV (Fig. 5A, panel
i). Persistent YVL-BR-specific clonotypes used significantly more of the shorter 9-mer
CDR3 and 10-, 11-, and 12-mer CDR3 than the nonpersistent clonotypes. In contrast,
the de novo clonotypes favored the longer 12-mer CDR3 and focused more on 11-mer
CDR3 length (Fig. 5B, panels i and ii). Significant changes in the GLC-BM-specific CDR3
length were also observed between AIM and CONV. For example, the frequencies of the
longer GLC-BM-specific 12-mer CDR3 and CDR clonotypes significantly increased
from 13.6% 6% and 6 2.8%, respectively, in AIM to 24% 5% and 17.9% 8%,
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FIG 4 Convergent recombination drives selection of persistent but not nonpersistent TCR repertoire:
decreased number of nucleotide additions in CDR3 of persistent EBV-specific TCR repertoire. (A, B, D, and
E) Number of nucleotide additions in the CDR3 of YVL-BR-specific (A and B) and GLC-BM-specific (D and
E) TCR and TCR of persistent, nonpersistent, and de novo repertoires (A and D) and private versus
public clonotypes (B and E). (C and F) Increased usage of glycines in the longer CDR3 of the de novo TCR
repertoire. Data were analyzed by multivariant two-way ANOVA with correction for multiple compari-
sons. *, P 0.05; **, P 0.01; ***, P 0.001. Error bars are SEM.
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respectively, in CONV, while use of the shorter 11-mer CDR3 decreased (Fig. 5A, panels
i and ii). The persistent clonotypes preferentially used 9- and 11-mer CDR3 while de
novo clonotypes used longer 12- and 14-mer lengths (Fig. 5B, panels iii and iv). The
persistent clonotypes also used 11- and 13-mer CDR3, while de novo clonotypes used
12-mer lengths.
Selection of the TCR and TCR repertoires was based on the features on the
specific epitope. To further elucidate factors that are driving selection of TCR specific
to the two immunodominant EBV epitopes, the characteristics of the TCR repertoires for
each of 3 donors were elucidated by systematically analyzing preferential TCRAV or BV
segment usage hierarchy as presented in pie charts, CDR3 length analyses, V-J pairing
by Circos plots of the clonotypes with the dominant CDR3 lengths, and dominant CDR3
motif; the last determines if there was an enrichment of particular amino acid residues
at specific sites potentially important for ligand interaction. Enrichment for certain
characteristics would suggest that these features are important for pMHC interaction
(11, 29, 47–50).
(i) The 9-mer TCR AV8.1-VKDTDK-AJ34 drives selection of YVL-BR-specific CD8
T cells. The YVL-BR-specific TCR repertoire was focused on one dominant family, AV8,
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used by all donors in AIM and CONV (Fig. 6A, panel i; also see Fig. S1A, panel i, in the
supplemental material). Similar strong selection bias was not observed in YVL-BR-
specific TCRBV usage; there was a great deal of interindividual variation and preferential
usage of multiple families, including BV6, BV20, BV28, and BV29 (Fig. 6B, panel i, and
Fig. S1B, panel i). Interestingly, in CONV, some TCRAV and BV gene families that
dominated in AIM became extinct or subdominant, or new dominant genes emerged
(Fig. 6, panels i).
Circos plot analyses of the pronounced 9-mer clonotypes showed that the dominant
AV8.1 gene almost exclusively paired with AJ34 (Fig. 6A and Fig. S1A, panel iii). CDR3
motif analysis revealed a pronounced motif, VKDTDK, in these shorter 9-mer clono-
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FIG 6 Nonamer TCR AV8.1-VKDTDK-AJ34 drives the selection of YVL-BR-specific CD8 T cells in AIM and CONV. HLA-A2/YVL-BR-specific TCR (A) and TCR
(B) repertoires were analyzed for 3 AIM donors (E1603, E1632, and E1655) during the acute (within 2 weeks of onset of symptoms; primary response) and
convalescent (6 months later; memory response) phases of EBV infection. The frequency of each TRAV (A) and TRBV (B) in total HLA-A2/YVL-BR-specific TCR
repertoire is shown in pie charts (i). The pie plots are labeled with gene families having a frequency of 10% (dominant; underlined) or between 5% and 10%
(subdominant; not underlined). The total number of unique clonotypes in each donor is shown below the pie charts. (ii) Circos plots depicting V-J gene pairing.
(iii) CDR3 motif analysis for the clonotypes with the two most dominant CDR3 lengths. Circos plots are shown for only the memory phase (AIM Circos plots
are shown in Fig. 7 and 8 and Fig. S1). The frequencies of V-J combinations are displayed in Circos plots, with the frequency of each V or J cassette represented
by its arc length and that of the V-J cassette combination by the width of the arc. “.un” denotes V families where the exact gene names were unknown.
Selection of EBV-Specific CD8 TCR Repertoire in AIM ®
March/April 2020 Volume 11 Issue 2 e00250-20 mbio.asm.org 9
 o
n
 April 15, 2020 at UNIV O
F M
ASS M
ED SCH
http://m
bio.asm
.org/
D
ow
nloaded from
 
types, representing 13.8%  5.6% of the total CD8 T cell response during acute AIM
(Fig. 6A, panel iii; Fig. S1A, panel iv; and Table S3A); 87% 1.7% of the clonotypes using
this motif were AV8.1, and 92%  1.7% were AJ34. Interestingly, this motif was present
in multiple other AV and AJ pairs, including AV12, AV21, and AV3. Obligate pairing of
the dominant AV8.1 response to AJ34 containing the highly conserved motif VKDTDK
was observed in all donors from AIM through CONV, suggesting that the 9-mer
AV8.1-VKDTDK-AJ34-expressing clones were highly selected. There was a preferential
usage of BV20-BJ2.7 pairing within the dominant 11-mer response (Fig. 6B, panel ii, and
Fig. S1B, panel iii), without an obvious CDR3motif (Fig. 6B, panel iii, and Fig. S1B, panel
iv), highlighting a great degree of diversity in the amino acid sequences. Within the
13-mer response (Fig. 6B, panel iii; Fig. S1B, panel iv; and Table S3B), the CDR3 motif
LLGG was commonly used. Clonotypes with this motif were only a minor part of the
overall responses in 2 donors (E1603, E1655) but composed 17.4% of the total YVL-BR
TCR repertoire in E1632.
Altogether, these results suggest that the 9-mer AV8.1-VKDTDK-AJ34-expressing
clones were highly preferentially selected by YVL-BR ligand during AIM and CONV and
that this TCR could pair with multiple different TCRs, as suggested by the fact that
there was no such dominant TCR clonotype. These findings have been independently
confirmed using single-cell sequencing (51).
(ii) AV5-EDNNA-AJ31-, BV14-SQSPGG-BJ2-, and BV20-SARD-BJ1 GLC-BM-
specific CD8 T cells are highly selected. GLC-BM-specific TCRAV and BV also had clear
preference for particular gene families, maintained from AIM to CONV, consistent with
prior reports (52, 53). We observed apparent preferential use of public AV5 and AV12
and BV20, BV14, BV9, BV28, and BV29 families (Fig. 7, panels i, and Fig. S2, panels i). Like
YVL-BR, there were some individual changes in the transition into CONV (Fig. 7, panels
i). Circos plot analysis of the dominant 9-mer CDR3 length clonotypes revealed a
conserved and dominant AV5-AJ31 pairing in all 3 donors (Fig. 7A, panel ii; Fig. S2A,
panel iii; and Fig. S3). A prominent motif, EDNNA, was identified within 9-mer clono-
types, of which 85%  11% were associated with AV5-AJ31 (Fig. 7A, panel iii; Fig. S2A,
panel iv; and Table S3C). This CDR3 motif was used by only 2.8%  1.7% of all
clonotypes recognizing GLC-BM in the 3 donors. The 11-mer CDR3 BV14-BJ2 pairing
exhibited a conserved, previously reported public motif, SQSPGG (54), which repre-
sented 26% and 40% of the total GLC-BM-specific response in donors E1632 and E1655
in AIM, respectively (Fig. S2B, panels ii to iv, and Table S3D). Within the CDR3 13-mer
response, a conserved BV20-BJ1 pairing, including the previously reported public motif
SARD, was used by all 3 donors and represented 11% 6% of the total GLC-BM-specific
response (Fig. 7B, panel iii; Fig. S2B, panels ii to iv; and Table S3D). Within the 13-mer
CDR3 response, there was also a consensus motif, SPTSG, present in all 3 donors,
which was used by multiple different BV families, which represented 20% and 2% of the
total response in donors E1632 and E1655, respectively, in AIM (Fig. 7B, panels ii to iv,
and Table S3D). These data suggest that, in contrast to YVL-BR, whose TCR repertoire
selection was primarily driven by TCR, the selection of the GLC-BM-specific TCR
repertoire in AIM was driven by a combination of TCR and .
Overall, despite individual changes, the dominant TCRV gene families and CDR3
motifs that were identified in AIM to drive the selection of YVL-BR- or GLC-BM-specific
CD8 T cells were predominantly conserved in CONV, suggesting the strength of these
TCR features in driving selection of the repertoire (Fig. 6 and 7 and Table S3).
Persistent, nonpersistent, and de novo clonotypes differ in selection factors. To
address whether clonotypes that persisted into memory show similar characteristics as
those that dominate in acute infection, YVL-BR and GLC-BM TCR/ repertoires were
compared between AIM and CONV. The TCR repertoire of persistent and nonpersistent
clonotypes in AIM and de novo clonotypes in CONV were examined in order to identify
selection factors that governed TCR persistence.
(i) YVL-BR persistent, nonpersistent, and de novo clonotypes have unique
characteristics. Persistent YVL-BR clonotypes maintained the major selection factors
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that were identified in AIM (Fig. 8A, Fig. S3 and S4, and Table S4). Although some
features were maintained in all 3 TCR subsets, there were significant structural differ-
ences in these repertoires.
The YVL-BR nonpersistent CDR3 clonotypes used AV8.1, but it was paired with
many more AJ gene families (Fig. S3). Moreover, AV8.1-VKDTDK-AJ34 clonotypes, which
were present in 42% 20% or 19% 11% of all persistent clonotypes during AIM or
CONV, respectively, were present in the nonpersistent response at a much lower mean
frequency (6% 1%) (Fig. 8A and Table S4A and B). The clonal composition of the
CDR3 nonpersistent response varied greatly in BV family usage between donors
(Table S4D and E) and lacked identifiable motifs, suggesting that for YVL clones
expressing AV8.1-VKDTDK-AJ34 to persist, there may be some preferential if not
obvious TCR characteristics that make them fit better.
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FIG 7 TCR (AV5-EDNNA-AJ31) and TCR (BV14-SQSPGG-BJ2 and BV20-SARD-BJ1) clones are dominant selection factors for GLC-BM-specific CD8 T cells in AIM
and CONV. HLA-A2/GLC-BM-specific TCRAV (A) and TCRBV (B) repertoires were analyzed for 3 AIM donors (E1603, E1632, and E1655) during the acute (within
2 weeks of onset of symptoms; primary response) and convalescent (6 months later; memory response) phases of EBV infection. The frequency of each TRAV
(A) and TRBV (B) in total HLA-A2/GLC-BM-specific TCR repertoire is shown in pie charts (i). The pie plots are labeled with gene families having a frequency of
10% (dominant; underlined) or between 5% and 10% (subdominant; not underlined). The total number of unique clonotypes in each donor is shown below
the pie charts. (ii) Circos plots depicting V-J gene pairing. (iii) CDR3 motif analysis for the clonotypes with the two most dominant CDR3 lengths. Circos plots
are shown for only the memory phase (AIM Circos plots are in Fig. S2 to S4). “.un” denotes V families where the exact gene names were unknown.
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For de novo clonotypes, new selection factors appeared that may relate to either a
decrease in antigen expression or a change in antigen-expressing cells over the course
of persistent infection. For instance, in the YVL-BR 9-mer de novo clonotypes, the
selection factor AV8.1-AJ34 was maintained in 2 of 3 donors and a new modified motif,
VKNTDK, was identified (Fig. 8A; Fig. S3A, panel i; and Table S4C). The de novo 11-mer
CDR3 response had increased usage of AV12 in all 3 donors (Fig. S3A, panel ii). In de
novo BV clonotypes, the pattern of BV-BJ usage changed compared to that observed in
AIM. Similarly, de novo 13-mer CDR3 clonotypes were also totally different with usage
of a new motif, SALLGX, in 2 of 3 donors (Table S4F).
(ii) GLC-BM persistent, nonpersistent, and de novo clonotypes have unique
characteristics. The persistent GLC-BM TCR clonotypes maintained the major selec-
tion criteria that were identified in AIM with the 9-mer EDNNA motif, which strongly
associated with AV5-1-AJ31, being present in a mean 5% 3.7% or 10% 8.6% of all
persistent clonotypes during AIM or CONV, respectively, in all 3 donors (Fig. 8B and
Table S4G). The fact that clonotypes using this motif were not present in nonpersistent
clonotypes suggests that this motif, and not just the gene family, may be important in
determining persistence of GLC-BM-specific clonotypes. The persistent GLC-BM-
repertoire also maintained the major selection criteria that were identified in AIM, with
the 11-mer SARD motif that strongly associated with BV20.1-BJ1 being present in a
mean 16% 9.9% or 24% 13.7% of all persistent clonotypes during AIM or CONV,
respectively, in all 3 donors. Two of the donors had the 11-mer SQSPGG motif
(Table S4I) in a mean 40% 8% and 30% 25% of all persistent clonotypes during AIM
or CONV, respectively.
Only the SARD motif clonotypes appeared in nonpersistent BV clonotypes during
AIM but at a lower mean frequency of 3% 1% (Table S4J). The de novo clonotype
selection appeared to be driven by different factors than that of the persistent
clonotypes. Although there were much greater diversity and more variation between
patients in de novo clonotypes (each donor is private) with recruitment of private AV
families such as AV41 or AV24 in E1632 and E1655, there was still a preferential usage
by 2 of 3 donors of AV5.1 (Fig. S5, panel i) and the appearance in 2 of 3 donors of a new
11-mer CDR3 motif, ELDGQ, which associated with AV5.1-AJ16.1 (Fig. 8B and Ta-
ble S4H). De novo clonotypes were also diverse and private using uncommon BV
families like BV7 and BV3 but also using common BV families such as BV20 (Fig. S6)
expressing the SARD motif in 5% 2.9% of de novo clonotypes (Fig. 8B and Table S4K).
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FIG 8 In both YVL-BR and GLC-BM responses, persistent clonotypes have characteristic CDR3 and CDR motifs that are distinct from
nonpersistent clonotypes. The de novo clonotypes appear to have new and unique CDR3 motifs. HLA-A2/YVL-BR (A)- and GLC-BM (B)-specific
TCR and TCR repertoires were analyzed for 3 AIM donors (E1603, E1632, and E1655) during the acute (within 2 weeks of onset of symptoms;
primary response) and convalescent (6 months later; memory response) phases of EBV infection. CDR3 motif analysis for the clonotypes within
the 3 different subsets, persistent, nonpersistent, and de novo, is shown.
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In conclusion, the persistent clonotypes made up the vast majority of the AIM and
CONV responses. For the most part, the nonpersistent clonotypes did not have a motif
despite the observation that some of them used a public TCR or TCR; this suggests
that one of the strongest selection factors for persistence was the CDR3 motif. Addi-
tionally, the fact that persistent clonotypes retained features that were identified in AIM
further supports their validity. Altogether, these results suggest that the HLA-A2-YVL-
BR- or GLC-BM-specific structure contributes strongly to the selection of dominant
persistent clonotypes.
DISCUSSION
This is the first study to use deep sequencing to comprehensively investigate the
TCR and TCR repertoires to two different EBV epitope-specific CD8 T cell responses
over the course of primary infection. We show that while epitope-specific TCR reper-
toires are highly diverse and vary greatly between donors, they are dominated by
distinct clonotypes with public features that persist into convalescence. These persis-
tent clonotypes have distinct features specific to each antigen that appear to drive their
peripheral selection; they account for only 9% of unique clonotypes but predominate
in acute infection and convalescence, accounting for 57%  4% of the total epitope-
specific response. Surprisingly, the majority of highly diverse unique clonotypes were
not detected following AIM and are replaced in convalescence by equally diverse de
novo clonotypes (43%  5% of the total response).
The deep-sequencing results show a highly diverse TCR repertoire in each epitope-
specific response with 1,292 to 15,448 and 1,644 to 7,631 unique clonotypes detected
within the YVL-BR- and GLC-BM-specific TCR-repertoires, respectively. Such diversity has
been underappreciated for the GLC-BM-specific TCR repertoire, with prior studies
reporting an oligoclonal repertoire (52, 53, 55). Despite this enormous diversity, there
was considerable bias. Although the TCR repertoire was individualized (i.e., each donor
studied had a unique TCR repertoire), there was prevalent and public usage of
particular TCRV families such as AV8 within the YVL-BR-specific responses and AV5,
AV12, BV14, and BV20 within the GLC-BM-specific populations.
One mechanism which may lead to the dominant public usage and persistence of
these clonotypes is that they have TCR features that increase their probability of
generation, i.e., they are potentially easier to derive. One of these features, convergent
recombination in both the TCR and the TCR CDR3, appears to play a major role in the
selection of these persistent clonotypes for expansion and maintenance into long-term
memory. This is evidenced by persistent clonotypes using more amino acids that have
multiple ways of being derived. A second feature is the usage of shorter germ
line-derived CDR3s with fewer nucleotide additions. The selection of unique public TCR
repertoire features, such as CDR3 length and particular TCRAV or BV family usage and
motifs, for each epitope in clonotypes that dominate and persist suggests that these
clones may be the best-fit TCR to recognize the pertinent pMHC complex. In contrast,
the broad repertoire of unique clonotypes that are activated in AIM, which is marked
by a high viral load and increased inflammation, may not fit as well and perhaps does
not receive a TCR signal that leads to survival into memory. Interestingly, 6 months after
the initial infection, a completely new (de novo) and similarly diverse TCR repertoire has
expanded. Continued antigenic exposure in persistent EBV infection may contribute to
the evolution of the TCR repertoire over time.
Prior studies using similar techniques to study influenza A virus (IAV) (not a persis-
tent virus) HLA-A2-restricted IAV-M158–67 and cytomegalovirus (CMV)-pp65 epitope-
specific memory responses showed a similar focused diversity of epitope-specific TCR
repertoires, suggesting that this is a general principle of antigen-specific repertoire
structure (29, 30). Altogether, these studies suggest that the pMHC structure drives
selection of the particular public featured dominant clonotypes for each epitope. The
broad fluctuating private repertoires show the resilience of memory repertoires and
may lend plasticity to antigen recognition, perhaps assisting in early cross-reactive CD8
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T cell responses to heterologous new pathogens (28, 56, 57) while at the same time
potentially protecting against T cell clonal loss and viral escape (58).
It is, however, possible that this difference in the private diverse portion of the
epitope-specific TCR repertoire between acute phase and convalescence may result
from sampling error as we are not able to analyze the full blood volume of an
individual. In order to at least partially address this, we have analyzed TCRAV and BV
deep-sequencing data from tetramer-sorted influenza A-M158-specific CD8 T cells (not
a persistent virus and thus not influencing TCR repertoire evolution) from one healthy
donor of a similar age from two time points 1 year apart. We compared the TCR overlap
of this antigen-specific population at two time points to the donors with AIM in this
paper. We calculated the overlap between clonotypes at two distinct visits (v1 versus
v7) using the Jaccard similarity coefficient J, which is defined as the size of the
intersection divided by the size of the union of two sets of clonotypes A and B. The
mean Jaccard similarity coefficient for TCRAV including both EBV epitopes during AIM
was 0.075  0.01 (n 6) and for TCRBV was 0.075  0.01 (n 6). A higher Jaccard
similarity coefficient was observed in the healthy donor for TCRVA (0.172) and for
TCRVB (0.208). The much higher Jaccard coefficients obtained for the healthy donor
suggest that the low overlap between clonotypes observed for acute- versus
convalescent-phase visits in EBV-infected individuals would not be due to sampling
alone. Also, the significant differences in the characteristics of the TCR repertoires of the
nonpersistent and de novo populations would suggest that these are different popu-
lations.
There have been limited reports of the importance of TCR in viral epitope-specific
responses. Biased TRAV12.2 usage with CDR1 interaction with the MHC has been
observed with the HLA-A2-restricted yellow fever virus epitope LLWWNGPMAV (59).
HLA-B*35:08-restricted EBV BZLF1-specific responses appear to be biased in both TCR
and TCR usage, much like HLA-A2-restricted EBV-BR (60, 61), with a strong preserva-
tion of a public TCR clonotype, AV19-CALSGFYNTDKLIF-J34, which can pair with a few
different TCR chains. TCR chain motifs have also been described for HLA-A2-
restricted influenza A virus M158–67 (IAV-M1), but these appear to make minor contri-
butions to the pMHC-TCR interaction, which is almost completely dominated by CDR3
(29, 45, 46).
The TCR repertoire of the HLA-A2-restricted IAV-M1 epitope is highly biased toward
the TRBV19 gene usage in many individuals and displays a strong preservation of a
dominant XRSX CDR3 motif. Crystal structures of TCR specific to this epitope have
revealed that the TCR is -centric with the conserved arginine in the CDR3 loop being
inserted into a pocket formed between the peptide and the 2 helix of the HLA-A2 (29,
62). The TCR has little role in pMHC engagement, and this helps explain the high
degree of sequence variability in the CDR3 and conservation in the CDR3. Similarly,
previous studies using EBV-GLC-BM-specific CD8 T cells have documented that TCR-
pMHC binding modes also contribute to TCR biases (63). The highly public HLA-A2-
restricted EBV-GLC-BM-specific AS01 TCR is highly selected because of a few very strong
interactions of its TRAV5- and TRBV20-encoded CDR3 loops with the peptide/MHC.
The present TCR deep-sequencing studies thus reinforce our previous report of an
underappreciated role for TCR-driven selection of the EBV-YVL-BR-specific repertoire
(Fig. 6) (51). To the best of our knowledge, our combined studies are among the first
to describe a TCR CDR3-driven selection of viral epitope-specific TCRs with minimal
contribution by the TCRBV. The AV8.1 family was used by all individuals and dominated
the conserved 9-mer response; it obligately paired with AJ34 and had a predominant
CDR3 motif, VKDTDK, representing 42% and 19% of the total persistent response in AIM
and CONV, respectively. In contrast, the BV response was highly diverse without
evidence of a strong selection factor, suggesting that AV8.1-VKDTDK-AJ34 could pair
with multiple different BV and still successfully be selected by YVL-BR-MHC. In contrast,
we did not find any of these AV8.1-VKDTDK-AJ34-expressing TCRs in a survey of deep
sequencing of sorted naive phenotype CD45RA CCR7 CD8 T cells from 3 age-
matched, healthy individuals (one EBV serologically negative and two EBV serologically
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positive). These results suggest that this clonotype is not inherently present at a high
frequency in the naive repertoire but requires interaction with EBV-YVL-BR to be
selected and expanded to these high frequencies.
In contrast, the selection of EBV-GLC-BM-specific TCR repertoire was driven by
strong interactions with both chains of TCR,  and , such as AV5.1-EDNNA-AJ31,
BV14-SQSPGG-BJ2, and BV20.1-SARD-BJ1, previously identified public features (43, 52,
53, 55). In a recent study comparing TCR and TCR repertoires of various human and
murine viral epitopes, none of the responses were primarily driven by interaction with
TCR alone; rather, they were predominantly driven by strong interactions with TCR
or a combination of TCR and TCR (11). This apparent preference of YVL-BR TCR
repertoires for particular TCRs may create a large repertoire of different memory
TCRs that could potentially cross-react with other ligands such as IAV-M158, which
predominantly interacts with TCR (11, 27, 29).
Using single-cell paired TCR sequencing of tetramer-sorted CD8 T cells ex vivo, we
have previously reported that at the at the clonal level recognition of the HLA-A2-
restricted EBV-YVL-BR epitope is mainly driven by the TCR chain (51). The CDR3motif
KDTDKL resulted from an obligate AV8.1-AJ34 pairing. This observation, coupled with
the fact that this public AV8.1-KDTDKL-AJ34 TCR pairs with multiple different TCR
chains within the same donor (median 4; range, 1 to 9), suggests that there are some
unique structural features of the interaction between the YVL-BR/MHC and the AV8.1-
KDTDKL-AJ34 TCR that lead to this high level of selection. TCR motif algorithms
identified a lysine at position 1 of the CDR3 motif that is highly conserved and likely
important for antigen recognition. Crystal structure analysis of the YVL-BR/HLA-A2
complex revealed that the MHC-bound peptide bulges at position 4, exposing a
negatively charged aspartic acid that may interact with the positively charged lysine of
CDR3. TCR cloning and site-directed mutagenesis of the CDR3 lysine ablated EBV-
BR-tetramer staining and function. Interestingly, we had previously used TCR structural
modeling of the EBV-YVL-BR/MHC complex to predict the occurrence of this important
protuberant lysine which might impact TCR interaction (64). Future structural analyses
will be important to ascertain whether the YVL-BR TCR contributes the majority of
contacts with the pMHC.
Altogether, our data provide several insights into potential mechanisms of TCR
selection and persistence. First, prior studies have revealed that selective use of
particular gene families can be explained in part by the fact that the specificity of TCR
for a pMHC complex is determined by contacts made between the germ line-encoded
regions within a V segment and the MHC (63, 65). We show here a highly unique
observation of a viral epitope-specific response being strongly selected based not only
on a particular TCRAV usage but a highly dominant CDR3motif and AV-AJ pairing (i.e.,
the YVL-BR-specific AV8.1-VKDTDK-AJ34 clonotype), with very little role for the TCRBV.
Second, it has been suggested that public TCRs represent clonotypes present at high
frequency in the naive precursor pool as they may be easier to generate in part as a
result of bias in the recombination machinery (66) or convergent recombination of key
contact sites (35, 37, 43, 63). Our data demonstrate that convergent recombination of
TCR, as well as TCR, may play a dominant role in peripheral selection of clonotypes
that are persistently detected through memory. As previously reported for TCR (35, 37,
43, 63), public clonotypes had a greater probability of being generated. They used more
convergent amino acids than private clonotypes, not only in the CDR3 but also in the
CDR3. YVL-BR TCR, which interestingly is not a strong selection factor for persistent
clonotypes, did not have public clonotypes with features that led to greater probablity
of being generated. Finally, we have previously reported that TCR immunodominance
patterns also seem to scale with the number of specific interactions required between
pMHC and TCR (29). It would seem that TCRs that find simpler solutions to being
generated and to recognizing antigen are easier to evolve and come to dominate the
memory pool (29). Consistent with this, our data demonstrate that the dominant
persistent clonotypes used shorter predominantly germ line-derived CDR3.
Despite the apparent nonpersistence of the vast majority of the initial pool of clones
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deployed during acute infection, clonotypic diversity remained high in memory as a
result of the recruitment of a diverse pool of new clonotypes. In a murine model,
adoptive transfer of epitope-specific CD8 T cells of known BV families from a single
virus-infected mouse to a naive mouse, followed by viral challenge, resulted in an
altered hierarchy of the clonotypes and the recruitment of new clonotypes, thus
maintaining diversity (67). A highly diverse repertoire should allow resilience against
loss of individual clonotypes with aging (45) and against skewing of the response after
infection with a cross-reactive pathogen (68–71). The large number of clonotypes
contributes to the overall memory T cell pool, enhancing the opportunity for protective
heterologous immunity now recognized to be an important aspect of immune matu-
ration (56, 72, 73). A large pool of TCR clonotypes could also provide increased
resistance to viral escape mutants common in persistent virus infections (58). Finally,
different TCRs may activate antigen-specific cell functions differently, leading to a more
functionally heterogeneous pool of memory cells (74).
In summary, our data reveal that apparent molecular constraints are associated with
TCR selection and persistence in the context of primary EBV infection. They also show
that TCR CDR3 alone can play an equally important role as CDR3 in TCR selection and
persistence of important immunodominant responses. Thus, to understand the rules of
TCR selection, both TCR and TCR repertoires should be studied. Such studies could
elucidate which of the features of the epitope-specific CD8 TCR are associated with an
effective response and control of EBV replication or disease.
MATERIALS AND METHODS
Study population. Three individuals of the age of 18 years (E1603, E1632, and E1655) who presented
with clinical symptoms consistent with acute infectious mononucleosis (AIM) and laboratory studies
indicative of primary infection (positive serum heterophile antibody and EBV viral capsid antigen
[VCA]-specific IgM) were studied as described previously (27). Blood samples were collected in heparin-
ized tubes at clinical presentation with AIM symptoms (acute phase) and 6 months later (memory phase).
Peripheral blood mononuclear cells (PBMC) were extracted with Ficoll-Paque density gradient medium.
Ethics statement. The Institutional Review Board of the University of Massachusetts Medical School
approved these studies (IRB protocol no. H-3698). All human subjects were adult and provided written
informed consent.
Flow cytometry and isolation of YVL-BR- and GLC-BM-specific CD8 T cells. The percentages of
peripheral blood antigen-specific CD8 T cells were measured using flow cytometry analysis. Antibodies
included anti-CD3–fluorescein isothiocyanate (FITC), anti-CD4–AF700, and anti-CD8–BV786; 7-aminoacti-
nomycin D (7AAD); and phycoerythrin (PE)-conjugated HLA-A*02:01 peptide tetramers (BRLF-1109–117, YVLD
HLIVV; BMLF-1280–288, GLCTLVAML). Tetramers were made and underwent quality assurance, as previously
described (75). Total CD8 T cells were enriched from PBMC by positive selection using magnetically
activated cell sorting (MACS) technology (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s
protocol. The cells were then stained with anti-CD3, anti-CD4, anti-CD8, 7AAD, and GLC-BM or YVL-BR
tetramers. Live CD3, CD8, and GLC-BM or YVL-BR tetramer cells were sorted by flow cytometry with
95% purity achieved (FACSAria III; BD) and were subjected to TCR analysis.
Analysis of TCR and TCR CDR3s using deep sequencing. The total RNA isolated from a
minimum of 10,000 tetramer CD8 T cells was reverse transcribed into cDNA and sent to Adaptive
Biotechnologies for TCR and TCR chain profiling following the protocols and standards for sequencing
and error correction that comprise the ImmunoSEQ platform. In summary, PCR amplification of the CDR3
is performed using specialized primers that anneal to the V and J recombination regions. Unique
molecular identifiers are added during library preparation to track template numbers. After sequencing,
CDR3 nucleotide regions are identified and clonal copy numbers are corrected for sequencing and PCR
error based on known error rates and clonal frequencies. Sequences of CDR3s were identified according
to the definition founded by the International ImMunoGeneTics collaboration. Deep-sequencing data of
TCR and TCR repertoires were analyzed using ImmunoSEQ Analyzer versions 2.0 and 3.0, which were
provided by Adaptive Biotechnologies. Only productively (without stop codon) rearranged TCR and
TCR sequences were used for repertoire analyses, including sequence amino acid composition and
gene frequency analyses. The frequencies of AV-AJ and BV-BJ gene combinations were analyzed with
subprograms of the ImmunoSEQ Analyzer software and further processed by Microsoft Excel.
Circos plots and motif analysis. The V and J gene segment combinations were illustrated as Circos
plots (76) across different CDR3 amino acid sequence lengths. Motif analysis was performed using the
Multiple EM for Motif Elicitation (MEME) framework (77). Consensus motifs were acquired across different
CDR3 lengths, and statistics on those motifs were computed with an in-house program called motif-
Search and available at http://github.com/thecodingdoc/motifSearch.
EBV DNA quantitation in B cells. B cells were purified from whole blood using the RosetteSep
human B cell enrichment cocktail according to the manufacturer’s recommendations (StemCell Tech-
nologies, Vancouver, BC, Canada). Cellular DNA was extracted using the Qiagen DNeasy blood and tissue
kit (Valencia, CA). Each DNA sample was diluted to 5 ng/l, and the Roche LightCycler EBV quantitation
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kit (Roche Diagnostics, Indianapolis, IN) was used to quantify EBV DNA copy number in the samples as
recommended by the manufacturer. Reactions were run in duplicate. B cell counts in each sample were
determined using a previously described PCR assay to quantify the copy number of the gene encoding
CCR5 (two copies per diploid cell) (78). Samples were normalized to B cell counts, and EBV DNA copy
number was calculated as DNA copy per 106 B cells.
Convergence analyses. The number of unique nucleotide sequences encoding an amino acid
sequence of TCRAV and TCRBV regions specific for YVL-BR and GLC-BM epitopes was calculated across
the pooled repertoires of all individuals. The number of nucleotide additions required to produce a
TCRAV or TCRBV sequence was determined by aligning the germ line V gene at the 5= end of the TCRAV
or TCRBV sequence and then the J gene segment at the 3= end of the TCR sequence. The germ line D
genes were subsequently aligned with nucleotides in the junction between the identified V and J
regions. Nucleotides identified in the junctions between the V, D, and J gene segments were considered
to be nucleotide additions. The significance values are based on multivariant two-way analysis of
variance (ANOVA).
Statistics. GraphPad Prism version 7.0 for Mac OSX (GraphPad Software, La Jolla, CA) was used for
all statistical analyses.
Data availability. Raw TCR deep-sequencing data are in immuneACCESS and can be accessed at
https://doi.org/10.21417/AG2020MBIO.
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